Big Bear ANADX Anagrelide 0.5mg

Product Information

• Product name: ANADX Anagrelide0 Anagrelide 0.5mg
• Manufacturer / brand: Laos BigBear Pharma
• Active ingredient: Anagrelide
• Current strength: 0.5mg
• SKU: Product ID 3136
• Site category: general medicines

Product Summary

ANADX Anagrelide0 Anagrelide 0.5mg is an AISTIKA-listed product supplied by Laos BigBear Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Anagrelide is the active ingredient used for this product page. Public prescribing information for Anagrelide was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

The precise mechanism by which Anagrelide reduces blood platelet count is unknown.

Reference Indications

Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

Reference Dosage and Administration

The starting dose for adults is 0.5 mg four times a day or 1 mg twice a day.

With this 0.5mg product, that corresponds to 2 x 0.5mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Cardiovascular Toxicity: QT prolongation and ventricular tachycardia have been reported with Anagrelide. Obtain a pre-treatment cardiovascular examination including an ECG in all patients. Monitor patients for cardiovascular effects. Pulmonary Hypertension: Assess underlying cardiopulmonary disease prior to initiating therapy. Bleeding Risk: Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding. Obtain a pre-treatment cardiovascular examination including an ECG in all patients. During treatment with Anagrelide monitor patients for cardiovascular effects and evaluate as necessary. Anagrelide increases the QTc interval of the electrocardiogram and increases the heart rate in healthy volunteers .

Common Adverse Reactions and Monitoring

Clinical Studies in Adult Patients In three single-arm clinical studies, 942 patients diagnosed with myeloproliferative neoplasms of varying etiology (ET: 551; PV: 117; OMPN: 274) were exposed to Anagrelide with a mean duration of approximately 65 weeks. Cardiac Disorders: Arrhythmia, angina pectoris, heart failure, syncope. Vascular Disorders: Hemorrhage, hypertension, postural hypotension, vasodilatation. Gastrointestinal Disorders: Constipation, gastrointestinal hemorrhage, gastritis. Blood and Lymphatic System Disorders: Anemia, thrombocytopenia, ecchymosis. Hepatobiliary Disorders: Elevated liver enzymes. Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia.

Drug Interactions and Special Populations

Other PDE 3 inhibitors: Exacerbation of inotropic effects Aspirin and Drugs that Increase Bleeding Risk: Increased risk of bleeding with concomitant use 7.1 Drugs that Prolong QT Avoid use of Anagrelide in patients taking medications that may prolong QT interval (including, but not limited to, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, and pimozide) . Avoid use of drug products with similar properties such as inotropes and other PDE3 inhibitors (e.g., cilostazol, milrinone) . Results from an observational study in patients with essential thrombocythemia suggest the rate of major hemorrhagic events (MHEs) in patients treated with Anagrelide is higher than in those subjects treated with another cytoreductive treatment.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Anagrelide public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.